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INTRODUCTION
It is now well recognized that donor T-cells can mediate
graft-versus-leukemia (GVL) responses in the setting of
allogeneic hematopoietic stem cell transplantation (HSCT)
[1]. However, many of those same alloreactive T-cells may
also induce graft-versus-host disease (GVHD), with its asso-
ciated high level of morbidity and mortality. Consequently,
in recent years much work has been directed toward devel-
opment of approaches that can separate the donor T-cell–
derived elements of GVL activity from the deleterious
development of GVHD.
One approach toward achieving this separation is to try
to take advantage of the differential dependency of cytotoxic
T-cells and their involvement in particular GVHD and
GVL responses. In regard to GVHD, immunohistochemi-
cal studies of epidermal tissue from allogeneic bone marrow
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ABSTRACT
L-leucyl-L-leucine methyl ester (LLME) prevents GVHD in several animal models by depleting dipeptidyl peptidase
I (DPPI)–expressing cytotoxic cellular subsets. However, clinical application has been hampered by difficulties in
stem cell engraftment following treatment of donor bone marrow inocula with LLME at the concentrations neces-
sary to purge DPPI-expressing T-cells. Noting that T-cells can mediate graft-versus-leukemia (GVL) responses via
both perforin (usually co-expressed in cytotoxic granules with DPPI) and Fas ligand pathways in a murine model, we
hypothesized that LLME might be useful for treatment of delayed DLIs for potential GVL activity with a decreased
risk of GVHD induction. In regard to the clinical setting, the ex vivo use of LLME for this purpose would circumvent
any toxicity issues for donor stem cells, because by that time patients would have already achieved successful engraft-
ment. For our preclinical studies, we used the haploidentical C57BL/6 (B6) (H2b) → ( (B6 × DBA/2)F1 (H2b/d) murine
model with lethally irradiated hosts that had received transplants of T-cell–depleted bone marrow cells and were
challenged with the MMD2-8 myeloid leukemia line (H2d) of DBA/2 origin. A DLI of LLME-treated donor spleno-
cytes, from B6 mice presensitized to recipient alloantigens, was administered in varying doses 14 days post–marrow
transplantation, and the potential for both GVHD and GVL activity was assessed. All mice that received any dose of
LLME-treated DLI survived indefinitely, without evidence of cachexia nor B-cell hypoplasia, in contrast to the severe
and lethal GVHD induced by mock-treated DLI. Histological analysis largely correlated with the symptomatic find-
ings and revealed no GVHD-like lesions in the spleens of LLME-treated DLI recipients, although some mice displayed
various degrees of hepatic mononuclear infiltration. Most notably, mice given LLME-treated DLI also experienced
DLI dose-dependent increases in survival against the challenge with the MMD2-8 leukemia. LLME-treated spleno-
cytes remained immunocompetent, as these cells could proliferate in response to mitogens and to restimulation with
ovalbumin when used as a recall antigen. In conclusion, LLME-treated DLI possesses immune potential and, in par-
ticular, GVL activity without inducing clinically evident GVHD.
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transplant recipients have correlated acute GVHD lesions
with the presence of perforin-containing cytolytic T-cells
[2,3]. Furthermore, in murine models of GVHD using
lethally irradiated hosts across major histocompatibility
complex (MHC) barriers, it has been demonstrated through
the use of perforin and Fas ligand (FasL)–deficient donor
mice that perforin expression is an important factor for
lethal disease development mediated by either one or both
CD4+ and CD8+ T-cells [4-6]. On the other hand, in other
models FasL pathways tend to dominate the involvement in
GVHD, although perforin expression still contributed to
the pathological development at some level [7,8]. Finally, in
MHC-matched minor histocompatibility antigen allogeneic
recipient mice, perforin appeared to be more important to
the development of severe GVHD-associated cachexia, but
less involved in hepatic or cutaneous disease [9].
In relation to GVL responses, the importance of per-
forin, FasL, and tumor necrosis factor-α (TNF-α) to the
overall mechanism of resistance may largely depend on the
T-cell subset mediating the effect and the nature of the
tumor cells under study. Of particular interest is the capacity
of the tumor cells to express MHC class II, likely required
for FasL and perforin-expressing CD4+ T-cells, and Fas or
TNF receptors with active downstream elements for apo-
ptosis induction by either CD4+ or CD8+ T-cells. It is not
surprising that murine GVL responses to tumors such as the
MHC class II–negative P815 mastocytoma line, which are
mediated by CD8+ cytotoxic T-lymphocytes (CTL), are
heavily dependent on perforin pathways, as this is a domi-
nant cytolytic mechanism for those effector cells [6,8]. In
contrast, many human acute and chronic myelogenous
leukemia cells express MHC class II and Fas molecules,
which may make them susceptible to CD4+ FasL+ effector
T-cells. Recently, in murine models for GVL responses to
myeloid leukemia lines, we demonstrated that CD4+ T-cells
could effectively use either perforin or FasL cytolytic path-
ways, with the latter being dominant in at least 1 setting
[10,11]. Considering these GVL results with the collective
data concerning involvement of perforin pathways at signiﬁ-
cant levels in GVHD development, we hypothesized that
elimination of perforin-positive donor T-cells would allow
effective GVL responses to a myeloid leukemia challenge
with minimal GVHD risk.
A previously attempted method to reduce GVHD
caused by T-cells in stem cell grafts has been the application
of L-leucyl-L-leucine methyl ester (LLME). LLME is a
lysosomotropic agent that is taken up by cells and converted
to pro-apoptotic metabolites by the action of intracellular
dipeptidyl peptidase I (DPPI), and it thus depletes cells con-
taining cytotoxic granules and perforin, most notably rele-
vant T-cell subsets [12]. LLME has been shown to reduce
or prevent GVHD in both mouse [13,14] and canine models
[15]. However, LLME was abandoned as GVHD prophy-
laxis after a clinical trial indicated that the concentrations
necessary to most effectively purge GVHD-inducing T-cells
in bone marrow grafts ex vivo resulted in failure to engraft
the human stem cells [16].
Noting the effectiveness of LLME in eliminating per-
forin-positive T-cells (mostly CD8+ and a small portion of
CD4+ cells [12,17]), yet the potential toxic effects on stem
cell engraftment, we considered whether we could avoid this
problem by using LLME to prevent delayed donor lympho-
cyte infusion (DLI)–associated GVHD. DLI was designed
to provide the benefits of a donor T-cell–mediated GVL
response with less risk of severe GVHD, theoretically
because the stimulatory environment and inflammatory
cytokine milieu following preconditioning regimens have
had time to recede several months after HSCT. The efﬁcacy
of DLI has been well established in preventing or treating
relapse of chronic myelogenous leukemia and shows
promise with acute myelogenous leukemia and acute lym-
phocytic leukemia [18,19]. However, the approach is still
plagued by relatively high frequencies of human GVHD. In
regard to the application of LLME, the advantage of ex vivo
treatment of DLI cells rather than of donor inoculum at
time of HSCT would be to decrease GVHD potential with-
out any possibility of stem cell toxicity, because the patient
would already have successful donor engraftment.
To test the effects of LLME treatment on DLI, we used
the haploidentical B6 (H2b) → ( (B6 × DBA/2)F1 (H2b/d)
irradiation model, reconstituted at day 0 with B6 anti-Thy-1
treated (T-cell–depleted) bone marrow (ATBM) and chal-
lenged on day 13 with the MMD2-8 myeloid leukemia line
of DBA/2 (H2d) origin. Administration on day 14 of a DLI
composed of splenocytes from B6 mice that had been pre-
sensitized to host alloantigens, resulted in dose-dependent
GVHD mortality. In contrast, LLME-treated DLI did not
cause GVHD, as assessed by multiple criteria, including
lethality, cachexia, lymphoid hypoplasia, and B-cell hypore-
sponsiveness to lipopolysaccharide (LPS) stimulation, even at
a maximum dose of 1.5 × 108 splenocytes. Pathological
analysis indicated only mild inﬁltration of mononuclear cells
in the livers of some mice given intermediate or high doses
of LLME-treated DLI, but there was no evidence of GVHD
in the spleens. Of most importance, LLME-treated DLI
splenocytes were still immunocompetent and could still
respond to stimulation in vitro to concanavalin A (ConA), to
alloantigens of host type and third party, and to a recall anti-
gen. Furthermore, LLME-treated DLI mediated signiﬁcant
and DLI dose-dependent in vivo GVL activity against the
MMD2-8 leukemia and signiﬁcantly prolonged survival.
MATERIALS AND METHODS
Mice
Male C57BL/6 (B6; H2b) and (B6 × DBA/2)F1 (B6D2;
H2b/d) mice were purchased from the National Cancer Insti-
tute Research and Development Center (Frederick, MD). B6
mice were used as donors between the ages of 7 and 12 weeks,
and B6D2 mice were used as recipients between the ages of
8 and 16 weeks. Mice were kept in a sterile environment in
microisolators at all times and were provided with acidiﬁed
water and autoclaved food ad libitum.
Cell Lines
WEHI 164 (CRL 1751), a methylcholanthrene-induced
ﬁbrosarcoma, was obtained from the American Type Culture
Collection (Manassas, VA). MMD2-8, a c-myc–transformed
myeloid leukemia line, was cloned from the ascites of a
DBA/2 mouse that had been injected with a c-myc–encoding
Moloney murine leukemia virus (MMLV) construct, as pre-
viously described [20].
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Media
Phosphate-buffered saline (PBS) supplemented with
0.1% bovine serum albumin (BSA; Sigma, St. Louis, MO)
was used for all in vitro manipulations of the donor bone
marrow and splenocytes, unless otherwise noted. Immedi-
ately prior to injection, cells were washed and resuspended
in PBS alone. Culturing of cell lines and in vitro assays were
performed in RPMI-1640, supplemented with 10% fetal
bovine serum (GIBCO, Grand Island, NY), 5.5 × 10–5 M
2-mercaptoethanol, 2 mM L-glutamine, 50 IU/mL peni-
cillin, and 50 µg/mL streptomycin (complete media).
GVL Survival Assay
All B6 donor mice used for DLI survival assays were
presensitized to recipient alloantigens by intraperitoneal
(i.p.) administration of 1.5 to 2.0 × 107 B6D2 splenocytes
12 days prior to use. LLME treatment of DLI was based on
previously outlined protocols [13]. Briefly, single cell sus-
pensions of spleens were lysed with Gey’s balanced salt
lysing solution containing 0.7% NH4Cl for removal of red
blood cells (RBC). Splenocytes were then washed and sus-
pended at 2.5 to 10 × 106 cells/mL in PBS containing 250 µM
LLME (Sigma). Cells were incubated for 15 minutes at
room temperature and then washed and resuspended in ice-
cold PBS. Splenocytes were promptly placed in culture or
infused in vivo. For mock-treated DLI, splenocytes were
subjected to identical conditions except that no LLME was
added to the incubation media.
Bone marrow cells were obtained from the femurs and
tibias of B6 mice by ﬂushing with PBS. To prepare ATBM,
cells were incubated with J1j monoclonal antibody (MoAb)
(1:100 dilution of ascites; TIB 184, American Type Culture
Collection) and guinea pig complement (1:25; Rockland,
Boyertown, PA) for 45 minutes at 37°C and were washed
twice in PBS containing 0.1% BSA before final resuspen-
sion in PBS.
B6D2 mice designated as recipients were given a total
of 13 Gy of ionizing radiation, given as a split dose of
6.5 Gy each separated by 4 hours, using a Shepherd Mark-I-
68A 137Cs source (1.43 Gy/min). One hour after the final
exposure, these mice were injected intravenously (i.v.) with
2 × 106 donor ATBM cells. On day 13 posttransplantation of
ATBM, half of the recipient mice were challenged with
105 MMD2-8 leukemia cells i.p. The following day, LLME-
or mock-treated DLI was prepared, as described above, and
administered i.v. to appropriate recipients. Mice were
checked daily for morbidity and mortality, median survival
times (MST) were determined, and statistical comparisons
were performed between experimental groups on data
pooled from 2 separate experiments using the nonparamet-
ric Tukey multiple analysis of variance.
Monoclonal Antibodies
Ascitic ﬂuid containing MoAb speciﬁc for Thy-1.2 (J1j)
was used for preparation of ATBM cells. For phenotyping of
MMD2-8 cells and splenocytes, fluorescein isothiocyanate
(FITC)–conjugated or phycoerythrin (PE)–conjugated ver-
sions of the following MoAb were purchased from Pharmin-
gen, San Diego, CA, and specific for: CD3ε (145-2C11),
CD4 (RM4-5), CD8α (53-6.7), CD11b/Mac-1 (M1/70),
CD13 (R3-242), CD45R/B220 (RA3-6B2), CD80/B7-1
(1G10), CD86/B7-2 (GL1), 2B4, Ly-6G/GR-1 (RB6-8C5),
H2Kd (SF1-1.1), H2Kb (AF6-88.5), and a rat immunoglobu-
lin (Ig) G2a isotype control (R35-95). Biotinylated anti-Fas
MoAb (Jo2) and a hamster IgG isotype standard (Ai9-3),
both from Pharmingen, as well as streptavidin (SA)-PE
(Caltag, South San Francisco, CA) were also used.
Flow Cytometry
Appropriate volumes of 25 µL of MoAB were each incu-
bated with 2 to 5 × 105 cells in a 96-well U-bottom micro-
titer plate for 25 minutes at 4°C, centrifuged at 1500 rpm
for 3 minutes, and washed with PBS containing 0.1% BSA
and 0.01% sodium azide (wash buffer). When applicable,
SA-PE or a secondary antibody was added in a volume of
25 µL for 25 minutes at 4°C, followed by 2 washes with
wash buffer. The ﬂuorescence analysis was performed on an
EPICS Profile II analyzer (Coulter, Hialeah, FL) in the
Kimmel Cancer Center Flow Cytometry Facility. The per-
centage of positive cells and the arithmetic mean fluores-
cence intensity were calculated for each sample.
For analysis of the effects of LLME treatment on
splenocyte subpopulations, cells were incubated with LLME
or PBS alone, as described above, and then placed in com-
plete media at 37°C for 3 hours to allow apoptosis to occur.
Splenocytes were then stained with fluorochrome-labeled
MoAb and subjected to ﬂow cytometric analysis.
For assessment of FasL expression after mitogenic stim-
ulation, LLME-treated B6D2 splenocytes were cultured at
4 × 106 cells/mL in 4 mL in 6-well plates with complete
media containing 10 mg/mL ConA. The cells were har-
vested after 48 hours and stained with either Fas-Fc or an
isotype control (Alexis, San Diego, CA), followed by anti-Fc
MoAb and then SA-PE, and analyzed by ﬂow cytometry.
TNF Receptor Reverse Transcriptase–Polymerase
Chain Reaction
Total cellular RNA was prepared from MMD2-8
leukemia cells. TNF receptor and GADPH primer sequences
have been previously described [21] and were provided by
Dr. Keith Kelley, University of Illinois, Urbana, IL. Reac-
tions were performed using a Perkin-Elmer Applied Biosys-
tems GeneAmp PCR System 9700. Cycling conditions were
30 minutes at 42°C; 2 minutes at 94°C; 30 cycles of 30 sec-
onds at 94°C, 45 seconds at 55°C, and 45 seconds at 72°C;
and ﬁnal extension for 7 minutes at 72°C. Product size was
determined by electrophoresing the samples on an agarose
gel and staining with ethidium bromide.
TNF-α Sensitivity Assays
Assay conditions to determine the sensitivity of MMD2-8
to exogenous TNF-α–mediated cytotoxicity were based on
previous studies [21,22]. MMD2-8 and WEHI164 cells
were cultured overnight at 2 × 104 cells/well in a volume of
100 µL in 96-well ﬂat bottom plates. Medium (100 µL) con-
taining either actinomycin D alone (0.5 µg/mL final) or
actinomycin D and titrated concentrations of recombinant
murine TNF-α (Peprotech, Rocky Hill, NJ) was added to
appropriate quadruplicate wells. After 22 hours, 70 µL was
aspirated from each well prior to addition of 50 µL of tetra-
zolium salt (MTT) (ﬁnal concentration 1 mg/mL). After a
4-hour incubation at 37°C, 50 µL of medium was aspirated
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and 150 µL of acidiﬁed isopropanol (0.04N HCl) was added
to each well. The medium in each well was then extensively
pipetted to dissolve crystals prior to measurement of each
well’s absorbance at 540 nm.
Cytotoxic Assays
B6 splenocytes were depleted of RBC with Gey’s bal-
anced salt lysing solution and then treated with LLME or
mock-treated, as described above. Cells (5 × 106) were cul-
tured in vitro for 5 days in upright 25 cm2 tissue culture
ﬂasks with 5 × 106 irradiated (15 Gy) B6D2 splenocytes and
1:20 of T-STIM culture supplement (Becton Dickinson
Labware, Franklin Lakes, NJ) in a total of 10 mL of com-
plete medium. MMD2-8 cells were labeled with 51Cr-
sodium chromate (ICN Radiochemicals, Irvine, CA) and
used as targets in a 6-hour 51Cr-release assay. To inhibit Fas-
mediated cytotoxicity, 5 µg/mL of a Fas fusion protein com-
posed of human recombinant fas combined with the Fc
region of human IgG1 (Fas-Fc) and 1 µg/mL of an antihu-
man IgG1-Fc antibody (enhancer protein) used for cross-
linking (Alexis) were added to relevant wells. As a control,
5 µg/mL of isotype-matched Fc fragment (Accurate Chemi-
cal, Westbury, NY) was substituted for the Fas-Fc. Percent
specific lysis was calculated as 100× experimental CPM
minus spontaneous release CPM (target cells in media
alone), divided by maximum release CPM (target cells in
cetrimide) minus spontaneous release CPM.
Proliferation Assays
B6 mice were immunized with ovalbumin (OVA) (150 µg;
Sigma) in Complete Freund’s Adjuvant containing H37RA
(Difco, Detroit, MI) subcutaneously 2 to 3 weeks before
priming them to recipient B6D2 splenocytes (1.5 × 107 i.p.).
Two weeks later, splenocytes from these mice were mock- or
LLME-treated, and the cells (2.5 × 105) were cultured in
96-well round-bottom plates with either ConA (2 µg/mL),
Escherichia coli LPS (20 µg/mL), B6D2 or C3H irradiated
(15 Gy) splenocytes (5 × 105), or OVA (75 µg/mL). Prolifer-
ative responses were determined after 3 to 5 days of cul-
ture by measuring [3H]-TdR incorporation following
an overnight pulse/label period. Quadruplicate samples
were used to calculate the mean incorporation and standard
deviations. A similar approach was used for examining
the responsiveness to LPS polyclonal B-cell activation of
B6D2 recipient splenocytes harvested 1 and 10 weeks post-
DLI. These cells were stimulated in vitro (105 per well) with
100 µg/mL LPS.
Histology
Mice were killed 10 weeks post-DLI, and tissues were
fixed in 10% formalin, embedded and sectioned (7 µm
thick) in parafﬁn wax, stained with hematoxylin and eosin,
and evaluated by light microscopy. Liver infiltrates were
considered “mild” if up to 25% of portal tracts featured
mononuclear infiltrates, and “severe” if >25% of portal
tracts were affected.
RESULTS
MMD2-8 Phenotype and Sensitivity to TNF-α
The c-myc–induced MMD2-8 leukemia cell line was
assessed phenotypically via flow cytometric analysis and
found to express high levels of surface H2Kd (98.4%),
CD11b/Mac-1 (99.4%), CD86/B7-2 (96.7%), CD13 (99.2%),
CD11a (72%), and CD95/Fas (96.8%). The cells expressed
intermediate levels of surface CD80/B7-1 (59.8%), Ly6G/
GR-1 (47.9%), and Ied (35.9%); low levels of CD45R/B220
(14.6%); and no FasL. This phenotype is consistent with the
monocytic-myeloid cell lineages known to be produced
through transduction with the c-myc–encoding retrovirus
[20,23]. The moderate to high expression of costimulatory
and both MHC classes I and II molecules suggested that
MMD2-8 could be capable of antigen presentation, and the
high level of surface Fas protein expression was consistent
with sensitivity to FasL-mediated apoptosis.
To determine whether MMD2-8 cells expressed TNF
type I or II receptors, reverse transcriptase–polymerase
chain reaction analysis was performed, because functional
expression levels of these surface molecules can be below the
threshold of detection by ﬂow cytometry [24]. Production of
mRNA for both TNF receptors was evident (data not
shown). Despite the presence of these receptors, MMD2-8
cells were resistant to exogenous TNF-α–mediated cytotox-
icity over a concentration range of 0.002 to 20 ng/mL, in
comparison to the WEHI164 cell line, which was highly
susceptible at all tested concentrations (Figure 1). These
ﬁndings suggested that MMD2-8 cells might be incapable
of transmitting apoptotic signals via the TNF receptor path-
way.
MMD2-8 Cells Can Be Lysed by LLME-Treated
Allogeneic CTL in a Fas-Dependent Manner
For determination of whether LLME-treated spleno-
cytes were capable of lysing MMD2-8 cells in vitro,
MMD2-8 cells were labeled with 51Cr-sodium chromate and
used as targets in a standard 6-hour 51Cr-release assay with
either in vitro B6D2-stimulated LLME- or mock-treated
B6 splenocytes as the CTL effectors (Figure 2). B6D2
Figure 1. Insensitivity of MMD2-8 cells to TNF-α–mediated cytotox-
icity. MMD2-8 myeloid leukemia and WEHI 164 cells were incubated
with various concentrations of TNF-α and a ﬁxed amount of actino-
mycin D (0.5 µg/mL ﬁnal). The percent speciﬁc lysis was analyzed by
an MTT assay, as described in Materials and Methods. Means and
standard deviations (all but one <5% of the mean) were calculated from
quadruplicate wells for all culture conditions.
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LPS-stimulated lymphoblasts were tested in parallel as
targets using the same effector cells. Mock-treated spleno-
cytes could effectively lyse B6D2 LPS-stimulated lym-
phoblasts, whereas LLME-treated effectors could not
(data not shown). Mock-treated CTL could also efﬁciently
lyse MMD2-8 target cells (peak killing of 44.7% at an effec-
tor:target [E:T] ratio of 33:1), whereas LLME-treated effec-
tors exhibited weaker activity (peak killing of 13.2% at an
E:T of 33:1, P < .01). However, this weaker LLME-treated
CTL activity appeared to be Fas-dependent, because addi-
tion of Fas-Fc, but not the irrelevant control Fc fusion pro-
tein, suppressed lysis to background levels (5.4% killing at
an E:T of 33:1), although this failed to reach statistical sig-
nificance (P > .05). These results suggested that LLME-
treated splenocytes could potentially mediate GVL activity
against MMD2-8 target cells, and possibly through direct
Fas-dependent cytotoxicity.
Phenotype of LLME-Treated Splenocytes
LLME- and mock-treated splenocytes from B6D2-
presensitized B6 mice were stained with fluorochrome-
labeled MoAb and analyzed by ﬂow cytometry. Most CD8+
T-cells (95.1%) were depleted, as well as most CD11b/
Mac1+ (94.6%) and all 2B4+ (100%) cells, which are myeloid
and natural killer (NK) cell markers, respectively (Table 1).
CD4+ T-cells appeared essentially unaffected, as well as
B220+ cells (B-cell marker), but both were proportionally
increased because of the loss of the other cellular subsets.
These ﬁndings were in agreement with the well-established
effects of LLME [13].
For determination of whether LLME-treated B6 spleno-
cytes had the capacity to express FasL, cells were cultured
with ConA (10 µg/mL) for 48 hours and then stained with
Fas-Fc or an isotype control, followed by anti-Fc MoAb and
then SA-PE. Both mock- and LLME-treated splenocytes
could express FasL after mitogenic stimulation, but the lat-
ter exhibited a 61% increase in the percentage of positive-
staining cells (16.8% and 27.0%, above isotype control
staining of 3.9% and 3.6%, respectively; Figure 3). In addi-
tion, the intensity of FasL expression nearly doubled for the
LLME-treated population (from mean ﬂuorescence inten-
sity values of 0.63 to 1.11). Without mitogenic stimulation,
neither mock- nor LLME-treated splenocytes expressed
detectable FasL.
The immunocompetency of LLME-treated B6 spleno-
cytes was assessed by in vitro proliferative responses to
mitogenic stimulation with either ConA or LPS, alloantigen
stimulation with recipient B6D2 or third-party strain (C3H)
splenocytes, and stimulation to a recall antigen, OVA (mice
had been immunized with OVA 2 to 3 weeks before also
priming them to recipient B6D2 alloantigens). The results
indicated that LLME-treated splenocytes were capable of
responding to all types of stimulation, although they did so
at a higher level and with somewhat delayed kinetics com-
pared to the mock-treated control group (Figure 4). This
observation may be due to the actually higher proportion of
CD4+ T-cells, and perhaps even B-cells serving as antigen-
presenting cells, in the splenocyte population following
LLME treatment. In summary, LLME depleted the major-
ity of CD8+ cells, in addition to myeloid and NK cells, and
possibly a small number of CD4+ cells, but preserved a pop-
ulation of cells that was capable of expressing FasL and of
responding to mitogenic stimulation, recipient and third-
party alloantigens, and a recall antigen.
LLME-Treated DLI Does Not Cause Lethal GVHD or
Associated Cachexia
B6D2 mice were lethally irradiated (13 Gy, split dose)
and reconstituted with B6 ATBM cells and 2 weeks later
were given graded doses (2, 4, and 15 × 107) of DLI in the
form of B6D2-presensitized B6 splenocytes that were either
LLME- or mock-treated ex vivo. Mice given mock-treated
DLI exhibited signiﬁcant dose-dependent GVHD with low
Figure 2. Lysis of MMD2-8 cells by mock- and LLME-treated allo-
geneic splenocytes. LLME or mock-treated B6 splenocytes were stimu-
lated with irradiated B6D2 splenocytes in a mixed lymphocyte reaction
and used as effectors against 51Cr-labeled MMD2-8 target cells in a
standard 6-hour 51Cr-release assay. To inhibit Fas-mediated cytotoxic-
ity, 5 µg/mL of Fas-Fc and 1 µg/mL of enhancer were added to one of
the LLME-treated groups, whereas an isotype matched Fc fragment
control was added to the other group. The mean percent speciﬁc cell
lysis was determined from triplicate wells, and the data are representa-
tive of 2 similar experiments.
Table 1. Flow Cytometric Analysis of Cell Lineages Comprising 
LLME-Treated Splenocytes*
Percent Positive Cells
Marker LLME-Treated Mock-Treated
CD4 30.1 29.1
CD8 0.6 12.2
B220 56.8 42.0
Mac-1 0.3 5.5
2B4 0 4.0
*For analysis of the effect of LLME treatment on B6 splenocyte
subpopulations, pooled cells were incubated with LLME or PBS alone
(mock) and then held in complete media at 37°C for 3 hours to allow
LLME-induced apoptosis to occur. Preparations were stained with
FITC-labeled MoAb and analyzed by ﬂow cytometry. The values rep-
resent the percent positive cells after subtraction of backgrounds
obtained by incubation with a FITC-labeled rat IgG2a control MoAb
(2.0% for LLME- and 1.8% for mock-treated groups).
M. H. Hsieh et al.
308
percentages of long-term survival, from 0% to 45%, and
MST of day 53 (2 × 107), day 16 (4 × 107), and day 14 (15 × 107;
Figure 5A). In contrast, all mice receiving any dose of
LLME-treated DLI survived indeﬁnitely (P < .05 compared
to all doses of mock-treated DLI). Other typical parameters
of GVHD, such as cachexia and weight loss, were evident in
all mock-treated groups, but not in those recipients of
LLME-treated DLI. For example, mice receiving the high-
est dose of 15 × 107 LLME-treated DLI maintained and
gradually increased their mean body weight throughout the
initial few weeks of observation and paralleled, if not
exceeded, the weights of the ATBM reconstituted recipients
(P > .05 at all time points; Figure 5B). It should also be
noted that LLME-treated splenocytes were not “dose
adjusted” for cellular subset equivalency to their mock-
treated control counterpart groups. Nevertheless, the same
question is approached by the dose titration, whereby 1.5 × 108
LLME-treated splenocytes failed to mediate lethal GVHD
with almost twice the number of CD8 cells as found in the
mock-treated 4 × 107 dose level (9.0 versus 4.8 × 106 cells,
respectively), which mediated severe GVHD.
Analysis of GVHD-Related Spleen and Liver Pathology
Spleen and liver samples were harvested from B6D2
mice 10 weeks after DLI administration. The tissues were
embedded and sectioned in paraffin wax and stained with
hematoxylin and eosin. All of the mice that received a low
dose (2 × 107 splenocytes) of mock-treated B6 DLI exhibited
Figure 3. Expression of FasL on mock-treated (A) and LLME-treated (B) splenocytes after culture with ConA (10 µg/mL) for 48 hours and stain-
ing with Fas-Fc protein or an isotype control, followed by anti-Fc MoAb and then SA-PE.
Figure 4. Proliferative responses of LLME-treated donor splenocytes. The immunocompetency of LLME-treated B6 splenocytes was assessed by
in vitro proliferative responses to mitogenic stimulation with either ConA or LPS (A), alloantigen stimulation with recipient B6D2 or third-party
strain (C3H) splenocytes (B), and stimulation to OVA, when used as a recall antigen. B6 mice were immunized with OVA 2 to 3 weeks before fur-
ther presensitization to recipient B6D2 splenocytes (1.5 × 107 i.p.). Two weeks later, the mock- or LLME-treated splenocytes were cultured with
either ConA (2 µg/mL), LPS (20 µg/mL), B6D2 or C3H irradiated (15 Gy) splenocytes, or OVA (75 µg/mL). Proliferative responses were deter-
mined after 2 to 5 days of culture by determining the mean [3H]-TdR incorporation from quadruplicate samples. The data are representative of 2
similar experiments. There was no signiﬁcant difference between the LLME and mock-treated responses to ConA stimulation on any of the days (P >
.05). Signiﬁcantly higher responses were obtained with the LLME-treated groups to LPS on all of the days (P < .05); to recipient stimulation on
days 3 to 5 (P < .02); to third-party stimulation on days 4 and 5 (P < .001); and to OVA on days 2 to 4 (P < .03).
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massive disruption of splenic architecture, including loss of
follicular organization (Figure 6A) and marked periportal
inﬁltrates in the liver (Figure 6B), consistent with GVHD
(80% of the mice had extensive inﬁltration; 20% had mild
inﬁltration). In contrast, the spleens of a majority (66%) of
the mice that were given 2 × 107 LLME-treated B6 DLI
displayed normal splenic architecture with intact follicles
(Figure 6C), whereas the remainder displayed only mild dis-
tortions. Livers were free of periportal inﬁltrates (Figure 6D),
similar to those of control mice given only ATBM cells with-
out DLI (not shown). At higher LLME-treated DLI doses of
either 4 × 107 or 1.5 × 108 splenocytes, the majority of mice
(66%) still exhibited no indications of GVHD pathology in
the spleen (Figure 6E for the intermediate dose), with the
remainder again expressing only minor involvement. Results
in the liver were variable in both dose groups, with some
mice (15%) still free of periportal inﬁltrates (Figure 6F, at
the 4 × 107 dose), whereas others had livers with scant (70%)
to extensive (15%) periportal inﬁltrates (not shown).
LLME-Treated DLI Maintains Donor Chimerism
without Lymphocyte Hypoplasia
B6D2 mice, 10 weeks after receiving doses of either 2, 4,
or 15 × 107 host-presensitized, LLME-treated B6 DLI, had
no obvious lymphoid hypoplasia in either the T-cell (CD4+
or CD8+) or B-cell (B220+) compartments, compared to
animals given ATBM cells alone without DLI. The mean
number of total cells per spleen ranged between 2.16 and
3.33 × 107 cells with donor chimerism between 88.4% and
98.4% (Table 2). In contrast, recipients of even a low dose of
mock-treated DLI had marked lymphoid hypoplasia with an
average of only 6.8 × 106 total cells/spleen, of which only
21.8% were B-cells. The remaining 42% of the cells were
Ly6G/Gr-1+ (granulocytes) and macrophages, a phenotype
most likely related to the immunopathological development
of GVHD. Overall, these results suggested that LLME-
treated DLI could maintain, if not enhance, donor chimerism
without inducing GVHD-associated hypoplasia in the late
post-DLI period.
LLME-Treated DLI Does Not Cause 
GVHD-Associated B-cell Hyporesponsiveness
To determine whether there was GVHD-associated B-cell
impairment in the splenic population of mice given LLME-
treated DLI, at 1 week posttransfer, splenocytes were tested
in vitro for mitogenic proliferative responses to LPS. At the
peak response after 4 days of culture, splenocytes from
B6D2 mice given 4 × 107 mock-treated B6 DLI proliferated
poorly in response to LPS with a mean of 7127 cpm, com-
pared to cells from mice given 4 × 107 LLME-treated DLI
or no DLI (22,931 and 33,205 cpm, respectively; P < .05)
(Figure 7A). This pattern was also maintained when
Figure 5. Effect of LLME-treated allogenic DLI on GVHD development. B6D2 mice were lethally irradiated, reconstituted with ATBM cells, and
2 weeks later given graded doses (2, 4, or 15 × 107) of host-presensitized mock- or LLME-treated B6 splenocyte DLI. A, Survival of mice given
DLI. The data were pooled from 2 similar experiments with combined n values indicated in the legend. B, Percent mean initial body weights of
mice given the 15 × 107 dose of DLI. The data are from 1 representative experiment (n = 6 per group).
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splenocytes were assayed on days 3 and 5 of culture. The
LLME-treated DLI was 31% lower (P < .05) than the no-
DLI group, but only on day 4 of assay, and, by comparison,
splenocytes from both groups responded less than spleno-
cytes from normal B6D2 mice.
LPS responses were also studied 10 weeks post-DLI,
using a maximum dose of host-presensitized B6 DLI (1.5 × 108
splenocytes/mouse). At 3 to 5 days of culture, splenocytes
from mice given LLME-treated DLI responded to LPS
similarly to those cells from mice without DLI, with a slight
25% decrease on day 4 (58,668 and 78,360 cpm, respec-
tively; P < .05; Figure 7B). These responses were well within
the range observed for normal splenocytes. Cells from
mock-treated mice were not tested because by this time the
mice had succumbed to GVHD.
LLME-Treated DLI Mediates GVL Activity
DLI has been found to be an effective approach for the
prevention or control of leukemic relapse by providing a
donor T-cell–mediated GVL response. It was, therefore,
imperative to test for the retention of this GVL capability
following the administration of LLME-treated DLI in our
experimental model. Lethally irradiated B6D2 mice recon-
stituted with B6 ATBM cells alone (no DLI) and challenged
Figure 6. Histological analysis of spleens and livers from mice that received DLI. Whole spleens and liver samples were harvested from mice sur-
viving 10 weeks after DLI, ﬁxed in formalin, embedded and sectioned in parafﬁn, and stained with hematoxylin and eosin. Spleen (A) and liver (B)
from a mouse that received a low dose (2 × 107 cells) of mock-treated splenocytes as DLI. Spleen (C) and liver (D) from a mouse given a low dose (2
× 107 cells) of LLME-treated splenocytes as DLI. Spleen (E) and liver (F) from a mouse given a medium dose (4 × 107 cells) of LLME-treated
splenocytes as DLI (original magniﬁcation ×10 for all panels).
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with 1 × 105 MMD2-8 myeloid leukemia cells on day 13 had
an MST of 26 days postchallenge with no long-term sur-
vivors (Figure 8). Mice similarly MMD2-8 challenged but
given a medium dose of mock-treated DLI (4 × 107 B6 host-
presensitized splenocytes) on day 14 had an MST of 13 days
postchallenge, with no survivors. These mice exhibited
clinical symptoms of GVHD before their demise. Mice
given leukemia challenge and 4 × 107 LLME-treated DLI
exhibited a significantly prolonged MST of 57 days in
comparison to either the ATBM control (P < .05) or the
mock-treated (P < .05) groups, with 27% surviving at the
termination of the experiment on day 70. Sample mice from
these survivors had no macroscopic evidence of leukemia
upon autopsy (data not shown).
Leukemia-challenged mice given a maximum mock-
treated DLI dose of 1.5 × 108 B6 host-presensitized spleno-
cytes had a MST of 15 days with no survivors (Figure 7). In
contrast, mice injected with LLME-treated DLI at that dose
had a MST of 60 days with 50% survival at 70 days. At time
of sacriﬁce, there was no evidence of widespread leukemia.
Instead, 2 of 3 sample mice from the survivors had evidence
of encapsulated leukemia in the peritoneum at the original
injection site. Collectively, these findings strongly suggest
that LLME-treated DLI is capable of mediating GVL
effects without overt development of GVHD, as reﬂected in
signiﬁcantly prolonged survival of transplant recipient mice.
DISCUSSION
GVHD remains a constant threat in the setting of
HSCT, whether mediated by T-cells contaminating the
stem cell graft or purposefully given in the form of DLI to
Table 2. Enumeration and Phenotypic Analysis of Splenocytes of Mice Given DLI*
Group No. of Cells, ×10–6 % Donor %CD4 %CD8 %B220
Normal B6 51.6 n/a 22.0 13.7 45.7
Normal B6D2 60.0 n/a 21.5 12.8 55.7
ATBM/No DLI 27.9 82.9 31.0 14.9 48.2
Mock-treated DLI (2 × 107) 6.8 90.4 26.6 9.6 21.8
LLME-treated DLI (2 × 107) 32.8 88.4 27.1 12.3 58.2
LLME-treated DLI (4 × 107) 21.6 98.4 20.1 11.0 49.7
LLME-treated DLI (1.5 × 108) 33.3 89.4 27.9 20.2 41.6
*Splenocytes were harvested and pooled from B6D2 recipients 10 weeks post-DLI with mock- or LLME-treated B6 donor lymphocytes. Viabil-
ity was determined by trypan blue exclusion, and cells were counted and phenotyped by ﬂow cytometry with appropriate FITC-labeled MoAb.
Analysis of H2Kb and H2Kd expression was used to measure donor chimerism. All values are expressed as the mean from pooled group samples (n =
3-5), and the data are from a representative experiment.
Figure 7. LPS-induced proliferation of splenocytes from mice given DLI. A, LPS-induced proliferation of splenocytes from B6D2 mice 1 week
post-DLI administration. Splenocytes from mice given ATBM cells alone (no DLI) or 4 × 107 host-presensitized LLME- or mock-treated B6
splenocytes as DLI were harvested and incubated alone or with LPS. Quadruplicate wells were pulsed overnight with [3H]-TdR, samples were col-
lected on days 3 to 5 of culture, and mean cpm and standard deviations were determined. Background samples of cells incubated without LPS
ranged between 159 and 516 cpm. B, LPS-induced proliferation of splenocytes from B6D2 mice 10 weeks post-DLI administration. Assays were
performed as described above, except that the original DLI dose was 1.5 × 108 host-presensitized LLME-treated B6 splenocytes. Background sam-
ples of cells incubated without LPS ranged between 151 and 1643 cpm.
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counteract leukemic relapse. Ex vivo LLME treatment of
donor bone marrow has been extensively investigated as a
means of GVHD prophylaxis. The agent has been found to
completely prevent the development of GVHD in multiple
models, including several allogeneic MHC- and minor his-
tocompatibility antigen–mismatched strain combinations
[13] and fully allogeneic MHC-mismatched systems [14]. In
these models, mice did not experience cachexia or other
clinical measures of GVHD, and the only microscopic signs
of disease were mild to moderate cholangitis and transient
skin infiltrates with residual dermal sclerosis [13,25].
Because GVHD-associated cachexia is classically associated
with TNF-α release [26,27] and LLME depletes DPPI-
expressing T-cells and myeloid cells, perhaps a significant
proportion of TNF-α–producing leukocytes also expresses
DPPI. This possibility may warrant further investigation.
It should be noted, however, that LLME only partially
prevented lethal GVHD in certain murine settings, includ-
ing an MHC class II–disparate model [B6 → ( (B6 × bm12)
F1] [28]; a host-presensitized, semiallogeneic MHC-mis-
matched combination (B6 → ( B6D2; the same system used
in this study) [29]; and a fully allogeneic MHC-mismatched
model (C3H → ( B6) [30]. All 3 studies were performed by
administering LLME-treated T-cells at the time of bone
marrow transplantation, whereas in the results reported
here, cells were given as DLI 2 weeks posttransplantation,
weakening the GVHD potential of the donor cells. Recog-
nizing the fact that in the semiallogeneic study, LLME
treatment only extended MST but did not increase the pro-
portion of long-term survivors, this model was nevertheless
adapted for assessing LLME-treated DLI capability because
of its relevance to clinical haploidentical HSCT.
LLME has likewise yielded somewhat mixed results in
canine studies. An initial study suggested that in vitro allo-
geneic proliferative responses as well as progenitor cell
colony counts were reduced by LLME treatment of canine
peripheral blood and marrow, respectively [31]. In another
study, administration of stem cell factor to dogs receiving
MHC-matched, LLME-treated bone marrow transplants
failed to enhance engraftment [32]. Yet an investigation of
the effects of LLME on canine GVHD demonstrated that
the agent was partially capable of preventing disease [15].
These ﬁndings in animal models complemented in vitro
studies with human cells, in which LLME could deplete
human NK cells, lymphokine-activated killer cells, mono-
cytes, certain T-cells, and granulocytes, but also reduced
human colony-forming unit (CFU) potential [17,33]. An
attempt to prevent the apparent human stem cell toxicity
of LLME by incubating CFU with interleukin-1 prior to
exposure resulted in increased CFU–granulocyte, erythro-
cyte, megakaryocyte, macrophage (GEMM), but not
CFU–granulocyte-macrophage (GM) or burst-forming unit,
erythroid (BFU-E) viability [34]. In this regard, it is likely
that the effect of LLME on stem cells is indirectly mediated
by its effect on accessory cells necessary for their survival,
rather than via direct toxicity on the stem cells themselves,
because they appear to lack DPPI activity (I. Weissman,
MD, Stanford University, personal communication, Novem-
ber 2000). Alternatively, it is possible that the observed fail-
ures of engraftment actually represented immunologic
rejection of the marrow, as can occur after marrow manipu-
lations such as T-cell depletion.
In a phase I clinical trial conducted to test the ability of
LLME to prevent GVHD, bone marrow grafts were incu-
bated ex vivo with LLME prior to infusion into patients
undergoing HLA-matched or -mismatched transplantation
[16]. The highest dose of LLME tested (500 µM) yielded a
signiﬁcant effect on acute GVHD development, with only
1 of 3 patients exhibiting grade I symptoms. Unfortunately, this
dose of LLME also resulted in suppression of CFU-GM, and
1 patient died from secondary graft failure, halting the study.
Based on the sizable body of work previously performed
on LLME and the potential problems encountered in stem
cell engraftment, we hypothesized that the more recent
development of DLI therapy might be more amenable to
the use of the agent as a means of GVHD prophylaxis. Any
effects of LLME on donor stem cells are irrelevant in the
setting of a DLI graft given to a patient who has already had
successful engraftment following HSCT. However, GVHD
is still a major concern with the DLI approach, considering
that the overall incidence of disease development is approxi-
mately 55% of all patients, half of whom experience grade II
and a quarter who experience grades III to IV levels of
severity with a high proportion of fatalities [18,19]. In
Figure 8. GVL capacity of LLME-treated DLI. B6D2 mice were lethally irradiated and reconstituted with B6 ATBM cells, and 13 days later all
mice were challenged with MMD2-8 myeloid leukemia cells (i.p.). The following day, mice were given mock- or LLME-treated B6 DLI (4 or 15 ×
107 host-presensitized splenocytes). Mice were monitored daily for survival, and the results represent pooled data from 2 similar experiments. The
sample size for each group is as indicated in the legend.
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smaller but more recent studies with HLA-identical DLI
patients, the incidence of severe acute GVHD ranged
between 8% and 40% [35,36]. Clearly, DLI-associated
GVHD remains a clinical problem, and, thus, LLME treat-
ment in this modality may be beneﬁcial.
In the murine model studied here, we demonstrate that
LLME treatment of DLI can prevent lethal GVHD and
associated cachexia, even at a physiologic maximum dose of
1.5 × 108 host-presensitized cells (Figure 4). This result is in
stark contrast to the rapid GVHD-induced deaths of mice
receiving an equivalent dose of mock-treated DLI (MST,
14 days). This observation is interesting considering that
non–perforin/granzyme-dependent cytolytic mechanisms
(ie, FasL/Fas) may still cause some level of GVHD in other
systems [7-9,37]. In the ﬁrst of 2 possibilities to account for
this difference in the DLI setting, there is likely to be a
decreased level of inflammatory cytokines available to up-
regulate Fas expression on relevant cells in target tissues.
Second, all of the other studies reporting FasL-mediated
GVHD effects involved either perforin-, granzyme-, or
DPPI-deficient mice that merely lacked the single gene
product. In contrast, LLME treatment of donor splenocytes
would likely eliminate all T-cells that contain cytotoxic
granules and DPPI, including those that might also coex-
press FasL or possess other inﬂammatory capabilities, such
as the production of TNF-α. Thus, either or both possibili-
ties could result in a vastly reduced GVHD potential of the
LLME-treated DLI population.
Histological analysis indicated that LLME treatment of
DLI could prevent GVHD-related pathology in the spleens
of recipients, but the treatment did variably result in some
hepatic periportal inﬁltrates at the highest donor cell doses
(see Results). The latter effect could be due to the activity of
FasL-bearing T-cells, because they have been postulated to
play a critical role in hepatic GVHD by targeting constitu-
tively Fas-expressing hepatocytes [27,30]. The gastrointesti-
nal tract is another organ in which Fas can be constitutively
expressed. However, gut samples did not exhibit histological
evidence of GVHD (data not shown), and the lack of any
weight loss in LLME-treated DLI recipients compared to
the control ATBM group (Figure 5) argues against any
pathological involvement in that GVHD target organ.
The data clearly suggest that mice receiving LLME-
treated DLI can still mediate a GVL response without con-
comitant clinical GVHD (Figure 8). Although the mechanism
of this effect is still unclear, it does not appear to involve
TNF-α, because the MMD2-8 leukemia cells are insensitive
to TNF-α–mediated lysis (Figure 1) and also produce their
own TNF-α cytokine. The FasL/Fas pathway is still a likely
candidate for GVL activity because of the high levels of con-
stitutive Fas expression on the MMD2-8 cells (Table 1).
Alternatively, other lytic pathways may be operative, such as
the TNF-related apoptosis-inducing ligand (TRAIL) [38].
Both activated human and mouse T-cells express TRAIL
[39,40], and this ligand can induce apoptosis by binding to a
number of receptors on target cells, including the Apo2/des-
ignated death receptor-4 (DR4)/TRAIL receptor-1 [41] and
DR5/TRAIL receptor-2 [42]. In this regard, it has been
demonstrated that mouse CD4+ T-lymphocytes expressing
TRAIL can lyse myeloid cells in a Fas-independent manner
[43]. The precise mechanism of the LLME-treated DLI
GVL effect observed in our model system is under further
investigation, including the phenotype of the effector cell in
anti-MMD2-8 CTL assays. We will also be examining
whether multiple infusions of LLME-treated DLI at lower
doses can further enhance the GVL effect.
In regard to other potential mechanisms by which
LLME-treated cells could mediate GVL activity, it is for-
mally possible that transferred CD4+ T-cells could still pro-
vide cytokine help for the true effector cells, eg, NK cells.
However, LLME also effectively eliminates NK cells, and it is
unlikely that there are any residual host lymphocytes, includ-
ing NK cells, after the high-dose radiation exposure (13 Gy,
split dose), although NK cells are the most rapidly reconsti-
tuting lymphoid population after human marrow transplanta-
tion [44]. Another remote possibility is that the DLI transfer
contains residual LLME at concentrations sufficient to
directly kill myeloid leukemia cells in vivo. However, NK
cells, the most LLME-sensitive leukocyte population, are
depleted in vivo only at a concentration of ≥500 µg/g body wt
of LLME, whereas in vitro depletion occurs efficiently in
9 µg/mL solutions (D. L. Thiele, MD, University of Texas
Southwestern Medical Center, personal communication,
2000). Considering that cells designated for use as DLI were
incubated in 250 µM (approximately 9 µg/mL) LLME and
washed twice with 50 mL PBS, it is highly unlikely that mice
received sufﬁcient LLME to deplete any cells.
The most interesting aspect of the LLME-treated DLI
approach is that the cells retain a significant level of
immunoresponsiveness, as demonstrated in earlier studies
[13,29,33] and in the current investigation. LLME treatment
of donor splenocytes left a large proportion of CD4+ T-cells
and B-cells intact (Table 2), and these cells were still respon-
sive in vitro to ConA or LPS mitogenic stimulation, as well as
to speciﬁc recall antigen (OVA) stimulation (Figure 4). Fur-
thermore, in addition to the above-mentioned retention of
GVL potential, splenocytes from recipient mice still exhibited
adequate proliferative responsiveness to LPS stimulation at
both 1 and 10 weeks post-DLI transfer, arguing against any
GVHD-induced B-cell dysfunction (Figure 7). These ﬁnd-
ings were also consistent with previous reports using the same
murine model but with administration of LLME-treated B6
splenocytes at the time of marrow transplantation [29]. How-
ever, our data are in contrast to another study suggesting that
GVHD-induced B-cell dysfunction is FasL-dependent and
not reliant on perforin-mediated mechanisms [45]. We appar-
ently do retain some FasL-mediated cytolytic potential (Fig-
ure 2), albeit at a level that might be below the threshold to
cause immunosuppressive B-cell dysfunction.
Because the ex vivo LLME treatment of donor lympho-
cytes can retain a signiﬁcant level of CD4+ T-cell and B-cell
immune functionality, the approach may be highly useful in
resolving the problem of poor immune reconstitution fol-
lowing haploidentical HSCT [44,46-48]. CD4+ T-cell
counts often remain at suboptimal levels (<150 counts/mL)
for up to 6 months or longer in these patients, and, as a
result, they are at high risk for opportunistic infections.
Because LLME spares the majority of CD4+ T-cells, the
transfer of these cells could potentially restore adequate
immunoresponsiveness, without high GVHD risk, until de
novo immune capability can be generated. DLI is already
administered to prevent or treat opportunistic infections, as
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well as leukemic relapse [47,49]. Ex vivo LLME treatment
of a DLI population would theoretically enable earlier post-
HSCT transfers and at higher doses to more effectively
restore immunocompetence to the patient. In this context, it
is noteworthy that recovery of CD8+ T-cells may occur
quite rapidly after conventional or T-cell–depleted HSCT,
whereas CD4+ T-cell recovery is far more delayed in both
patient groups. The preservation of CD4+ T-cells in the
DLI thus might complement the endogenous lymphocyte
redevelopment occurring in vivo. In light of these potential
advantages and the preclinical results, a phase I clinical trial
has been initiated to test the ability of LLME-treated DLI
to accelerate functional immune recovery after HSCT while
minimizing the risks of developing severe GVHD.
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